Alle Storys
Folgen
Keine Story von november Aktiengesellschaft mehr verpassen.

november Aktiengesellschaft

EANS-News: november Aktiengesellschaft
November AG subsidiary PROGEN signs exclusive distribution agreement with Asuragen

Cologne (euro adhoc) -

New: KRAS/BRAF Test for Luminex-User
New: AmplideX FMR1 PCR-Assay
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
New Products/Research & Development/Distribution
Subtitle: New: KRAS/BRAF Test for Luminex-User
New: AmplideX FMR1 PCR-Assay
PROGEN Biotechnik GmbH, a daughter of the
November AG, has signed an exclusive distribution contract for 
Germany with the U.S.A. based Asuragen Inc., a company focused on 
personalized medicine and companion diagnostics in the field of 
oncology and human genetics.
PROGEN is now in a position to further expand its product line of 
multiplexed assays enabling the detection of mutations often found in
solid tumors, such as KRAS or BRAF, and fusion transcripts or 
mutations associated with specific leukemia types or subtypes. These 
assays incorporate Signature® technology which is optimized for the 
rapid multiplex analysis of nucleic acid sequences in a single 
reaction, thus enhancing operational efficiencies through reduced 
costs and streamlined workflow. The signature® reagents are adapted 
for use on the Luminex® platform.
Additionally, PROGEN offers now two state-of-the-art PCR 
technologies, developed by Asuragen, for molecular characterization 
of the trinucleotide repeat in the 5´ region of the fragile X mental 
retardation (FMR1) gene for routine screening testing. The highly 
sensitive and time-saving assay is suited for the detection of FMR1 
mutations in pre- and postnatal diagnosis and allows initiating early
measures for improvement of the living conditions of the patients.
PROGEN is thereby extending its product line of biomarker/molecular 
diagnostics, and Luminex®-based tests for further assays. Thus, the 
company is consequently pursuing its strategy to offer a broad 
portfolio of own developed tests as well as products from other 
manufacturers.
About Luminex® Technology The xMAP® (Multi Analyte Profiling) 
technology developed by Luminex® (www.luminexcorp.com) is an 
innovative assay platform for a large range of applications. With 
this technology it is possible to simultaneously test 100 parameters 
in one test run. Thus, the user saves time and sample material. The 
technology is based on microscopically small polystyrene beads which 
are coated with antigens e.g. against different infectious diseases. 
The automated process allows the beads to identify up to 100 
different analytes from one sample. This very sensitive and specific 
detection enables fast screening tests of many different samples as 
well as a differential sample analysis.
About november AG / PROGEN Biotechnik GmbH november AG, Koeln 
(www.november.de) is an investment and holding company, listed in the
prime standard of the regulated market of the German stock exchange 
(Deutsche Börse), with special focus on medical technology, 
biotechnology, and environmental technologies and 100% shareholder of
PROGEN Biotechnik GmbH. PROGEN Biotechnik GmbH, Heidelberg 
(www.progen.de), is manufacturer of in vitro diagnostics (borrelia, 
hanta virus, FSME) and research reagents (antibodies, polypeptides, 
AAV, hyperphage, www.hyperphage.com), certified to DIN EN ISO 
13485:2007, as well as for the production of multiplex assays for the
Luminex® platform. PROGEN is member of the VDGH (German Association 
of Diagnostic Manufacturers).
About Asuragen Inc. Asuragen Inc., Austin, USA, (www.asuragen.com) is
a fully integrated molecular diagnostic company focused on 
personalized medicine and companion diagnostics, with emphasis on 
mRNA/miRNA applications in oncology. As an FDA-registered medical 
device manufacturer Asuragen offers cGMP development and 
manufacturing capabilities available for contract manufacture with a 
special focus on in vitro transcribed RNA. Asuragen has become a 
leader in companion diagnostics by discovering and developing 
predictive and prognostic test for its pharmaceutical and 
biotechnology partners.
end of announcement                               euro adhoc

Further inquiry note:

Dr. Dirk Zurek
CEO
Tel.: +49 (0) 221 82200 520 10
E-Mail: ir@november.de

Branche: Biotechnology
ISIN: DE000A0Z24E9
WKN: A0Z24E
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade

Weitere Storys: november Aktiengesellschaft
Weitere Storys: november Aktiengesellschaft